Compare ASMB & SNAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | SNAL |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.8M | 29.8M |
| IPO Year | 2010 | 2022 |
| Metric | ASMB | SNAL |
|---|---|---|
| Price | $27.84 | $0.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $43.40 | N/A |
| AVG Volume (30 Days) | ★ 109.9K | 21.1K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $37,191,000.00 | ★ $82,330,445.00 |
| Revenue This Year | $33.33 | N/A |
| Revenue Next Year | N/A | $50.41 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.30 | N/A |
| 52 Week Low | $7.75 | $0.64 |
| 52 Week High | $39.71 | $3.42 |
| Indicator | ASMB | SNAL |
|---|---|---|
| Relative Strength Index (RSI) | 37.34 | 36.45 |
| Support Level | $25.93 | $0.78 |
| Resistance Level | $32.31 | $0.83 |
| Average True Range (ATR) | 1.74 | 0.05 |
| MACD | -0.43 | -0.00 |
| Stochastic Oscillator | 25.06 | 40.56 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.